Companion Diagnostics Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> - Size,<br />
Share, Outlook, and Opportunity<br />
Analysis, 2018 - 2026<br />
Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong>, By Application(Breast Cancer, Lung<br />
Cancer, Colorectal Cancer, Gastric Cancer, Melanoma),<br />
Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH),<br />
and Geography - Trends, Analysis and Forecast till 2026<br />
Personalized medicine is the new segment in discussion among healthcare experts around the<br />
globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of<br />
providing a defined structure for companion diagnostic development is driving research activities<br />
in personalized medicine. Diagnosis at molecular level for each individual is of prime importance<br />
to identify the target biomarker before deciding the therapy. <strong>Companion</strong> diagnostic is one such<br />
emerging field for target biomarker identification reducing clinical trial cost and time to market<br />
the product.<br />
Pharmaceutical companies need to constantly innovate and integrate latest technological<br />
breakthroughs in order to sustain in the companion diagnostics market, given the looming threat<br />
of new technologies posing threat to existing product portfolio and research pipeline. Novartis AG<br />
focuses on R&D for biomarkers with the help of its partner SomaLogic, Inc., once they begin the<br />
process of finalizing the drug candidate. Such pre-work is now part of the routine of drug<br />
development, something that was an alien practice till around a decade ago. The U.S. FDA<br />
released a draft guideline for companion diagnostics in July 2016, providing a structure for the<br />
pharmaceutical companies to co-develop CDx test along with the drug therapies.<br />
Request Sample Copy of this Business Report @<br />
https://www.coherentmarketinsights.com/insight/request-sample/109<br />
Low cost and clinical benefits of companion diagnostics is expected to drive growth of<br />
the market<br />
The ecosystem of pharmaceuticals industry is one of the major factors driving growth of the<br />
companion diagnostics market. The providers of healthcare products and services, and patients<br />
who utilize these products and services is expected to be benefitted by a collaborative approach.<br />
The innovation of CDx helped drug developers in reducing the development costs, developing<br />
highly effective therapeutic products, and improving the time to market by identifying the
effectiveness of a drug against particular biomarkers. Moreover, better treatment outcomes and<br />
lower morbidity risk are benefits offered to the patients. Also, accurate diagnosis and<br />
determination of targeted cancer therapy has become much easier due to advanced<br />
technologies such as PCR, immunohistochemistry, and gene sequencing.<br />
<strong>Companion</strong> diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug<br />
therapy to the patient. It has become a critical part of targeted cancer therapy that allows for<br />
development of personalized therapy can be developed and administered to the patient. Whole<br />
blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and<br />
identification of targeted disease biomarker. CDx is usually utilized in identifying genetic<br />
mutations and the health and treatment approach implications. In July 2016, the U.S. FDA<br />
released a draft guideline for development of a therapeutic product accompanying an IVD<br />
companion diagnostic. <strong>Companion</strong> diagnostics include Gleevec (imatinib mesylate) and BCR-ABL<br />
LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex<br />
(tamoxifen) and laboratory-developed estrogen receptor positive test.<br />
<strong>Companion</strong> diagnostics are beneficial for pharmaceutical companies who face challenges with<br />
respect to high drug development cost, safety and outcome of clinical trials, and long product<br />
approval time. <strong>Companion</strong> diagnostics lowers development costs, improves time to market and<br />
enhances drug safety by enabling rapid identification of target biomarker and the most effective<br />
drug therapy. For patients, the technology provides better treatment outcomes and lower<br />
morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing<br />
has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests<br />
also aid in revealing the off-target effects of a drug along with identification of a molecular<br />
target, CDx have become and indispensable tool for oncologists.<br />
Browse More About the Keyword <strong>Market</strong> Study @<br />
https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109<br />
Report includes chapters which deeply display the following deliverable about industry:<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Research Objective and Assumption<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Purview - Report Description, Executive Summary, and<br />
Coherent Opportunity Map (COM)<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Dynamics, Regulations, and Trends Analysis - <strong>Market</strong><br />
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system<br />
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis<br />
• Global Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong>, By Regions<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Competition by Manufacturers including Production, Share,<br />
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Manufacturers Profiles/Analysis including Company Basic<br />
Information, Manufacturing Base and Its Competitors.<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Manufacturing Cost Analysis including Key Raw Materials<br />
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials<br />
Sourcing and Downstream Buyers<br />
• <strong>Market</strong>ing Strategy Analysis, Distributors/Traders including <strong>Market</strong>ing Channel, <strong>Market</strong> Positioning<br />
and Distributors/Traders List.<br />
• <strong>Market</strong> Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer<br />
Preference Change and Economic/Political Environmental Change.<br />
• Global <strong>Companion</strong> <strong>Diagnostics</strong> <strong>Market</strong> Forecast including Production, Consumption, Import and<br />
Export Forecast by Type, Applications and Region.<br />
• Research Findings and Conclusion<br />
Table of Contents of Keyword <strong>Market</strong> Report:<br />
1. Research Objective and assumption<br />
2. <strong>Market</strong> Purview<br />
3. <strong>Market</strong> Dynamics, Regulations, and Trends Analysis<br />
4. Keyword <strong>Market</strong>, By Advanced Water Meters, 2017 - 2025 (USD Million)<br />
5. Keyword <strong>Market</strong>, By Service, 2017 - 2025 (USD Million)<br />
6. Keyword <strong>Market</strong>, By Solution, 2017 - 2025 (USD Million)<br />
7. Keyword <strong>Market</strong>, By Regions, 2017 - 2025 (USD Million)<br />
8. Competitive Landscape<br />
Ask for Discount before Buying @<br />
https://www.coherentmarketinsights.com/insight/request-discount/109<br />
About Coherent <strong>Market</strong> Insights:<br />
Coherent <strong>Market</strong> Insights is a prominent market research and consulting firm offering action-ready<br />
syndicated research reports, custom market analysis, consulting services, and competitive analysis<br />
through various recommendations related to emerging market trends, technologies, and potential<br />
absolute dollar opportunity.<br />
Contact Us:<br />
Mr. Shah<br />
Coherent <strong>Market</strong> Insights<br />
1001 4th Ave,<br />
#3200<br />
Seattle, WA 98154<br />
Tel: +1-206-701-6702<br />
Email: sales@coherentmarketinsights.com